Factors associated with insurance coverage of tofacitinib for alopecia areata: A retrospective review from an academic institution
To the Editor: It has become increasingly recognized that JAK inhibitors (JAKis) have substantial efficacy in the treatment of alopecia areata (AA).1 JAKis approved by the US Food and Drug Administration (FDA) are currently under patent in the United States and can be expensive. The high cost of medication is a significant obstacle for patients, and, in the United States, the vast majority rely…
